Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (brevity).
Authors
Gibb, AdamPirrie, S
Linton, Kim M
Paterson, K
Davies, A
Collins, G
Menne,T
McKay, P
Fields, P
Miall, F
Nagy, E
Wheatly, K
Warbey, V
Barrington, S
Radford, John A
Affiliation
The Christie NHS Foundation Trust, Manchester, UKIssue Date
2016